nach oben

Supportive Care in Cancer

Erschienen in:

01.11.2007 | Review Article

Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review

verfasst von: Ingo J. Diel

Erschienen in: Supportive Care in Cancer | Ausgabe 11/2007

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Almost all patients with breast cancer and bone metastases suffer bone pain. Many receive bisphosphonate therapy only when the pain becomes unbearable or there is a direct threat of skeletal complications.

Discussion

However, clinical trial data demonstrate that bisphosphonates offer significant and sustained relief from bone pain and can also improve quality of life in patients with metastatic breast cancer.

Conclusion

Moreover, new treatment schedules using high dose bisphosphonates can offer rapid relief of acute, severe bone pain.

Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbonova VA, Budde M, Bergström B; MF 4265 Study Group (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14(9):1399–1405PubMedCrossRef

Body JJ, Bell R, Pecherstorfer M, Lichinitser MR, Lazerev AF, Tripathy D, Bergström B (2004) Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111(3):306–312PubMedCrossRef

Body JJ, Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, Tripathy D, Bergström B (2004) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease; results from two randomized, placebo-controlled phase III studies. Br J Cancer 90(6):1133–1137PubMedCrossRef

Conte PF, Latreille L, Mauriac L, Calabresi F, Santos R, Campos D, Bonneterre J, Francini G, Ford JM (1996) Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 14(9):2352–2359

Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BY, Verma S, Pritchard KI, Trudeau M, Cole DE (2006) Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 24(30):4895–4900PubMedCrossRef

Diel IJ, Body JJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergström B; MF4265 Study Group (2004) Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 40(11):1704–1712PubMedCrossRef

Diel IJ, Solomayer EF, Bastert G (2000) Treatment of metastatic bone disease in breast cancer: bisphosphonates. Clin Breast Cancer 1(1):43–51PubMedCrossRef

Donnelly S, Walsh D (1995) The symptoms of advanced cancer. Semin Oncol 2(Suppl 3):67–75

Heidenreich A, Ohlmann C, Olbert P, Hegele A (2003) High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Eur J Cancer (Suppl 1):S270

10.

Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21(21):4042–4057PubMedCrossRef

11.

Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335(24):1785–1791PubMedCrossRef

12.

Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Knight RD, Heffernan M, Mellars K, Reitsma DJ (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16(6):2038–2044PubMed

13.

Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23(15):3314–3321PubMedCrossRef

14.

Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT (1999) Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 246(1):67–74PubMedCrossRef

15.

Kurth AA, Pilz M, Stumpf U, Müller A, Eberhardt C (2006) Reduced bone pain by intensive bisphosphonate-therapy of new diagnosed bone metastases. Bone 38(3 Suppl 1):S77

16.

Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Hefferman M, Seaman JJ (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in woman with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88(5):1082–1090PubMedCrossRef

17.

Mancini I, Dumon JC, Body JJ (2004) Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 22(17):3587–3592PubMedCrossRef

18.

Mustchin E, Valentini M (2006) Communication barriers delay effective treatment of metastatic bone pain: European market research results. Ann Oncol 17(Suppl 9):78

19.

Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11(1):59–65PubMed

20.

Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev 3:CD003474PubMed

21.

Robertson AG, Reed NS, Ralston SH (1995) Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 13(9):2427–2430PubMed

22.

Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussain MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast cancer. Cancer 98(8):1735–1744PubMedCrossRef

23.

Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL, Coleman RE (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100(1):36–43PubMedCrossRef

24.

Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind comparative trial. Cancer J 7(5):377–387PubMed

25.

Siris ES, Hyman GA, Canfield RE (1983) Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. Am J Med 74(3):401–406PubMedCrossRef

26.

Slatkin N (2006) Cancer-related pain and its pharmacologic management in the patient with bone metastasis. J Support Oncol 4(2 Suppl 1):15–21PubMed

27.

Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G (2000) Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 59(3):271–278PubMedCrossRef

28.

Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Hefferman M, Reitsma DJ (1999) Pamidronate reduces skeletal morbidity in woman with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 17(3):846–854PubMed

29.

Thürlimann B, Morant R, Jungi WF, Radziwill A (1994) Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study. Support Care Cancer 2(1):61–65PubMedCrossRef

30.

Van Holten-Verzantvoort AT, Kroon HM, Bijvoet OL, Cleton FJ, Beex LV, Blijham G, Hermans J, Neijt JP, Papapoulos SE, Sleeboom HP et al (1993) Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 11(3):491–498PubMed

31.

Van Holten-Verzantvoort AT, Aaronson NK, Hermans J, van Emmerik B, van Dam FS, van den Bos B, Bijvoet OL, Cleton FJ (1991) The effect of supportive treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer 27(5):544–549PubMedCrossRef

32.

Vogel CL, Yanagihara RH, Wood AJ, Schnell FM, Henderson C, Kaplan BH, Purdy MH, Orlowski R, Decker JL, Lacerna L, Hohneker JA (2004) Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist 9(6):687–695PubMedCrossRef

33.

Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron D (2005) Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised crossover study of community vs. hospital bisphosphonate administration. Br J Cancer 92(10):1869–1876PubMedCrossRef

Titel: Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review
verfasst von: Ingo J. Diel
Publikationsdatum: 01.11.2007
Verlag: Springer-Verlag
Erschienen in: Supportive Care in Cancer / Ausgabe 11/2007
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-007-0244-9

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review

Abstract

Introduction

Discussion

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Introduction

Discussion

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2007

Intraclass correlation metrics for the accuracy of algorithmic definitions in a computerized decision support system for supportive cancer care

The associations between living conditions, demography, and the ‘impact of cancer’ scale in tumor-free cancer survivors: a NOCWO study

Developing supportive care for family members of people with lung cancer: a feasibility study

Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer

Measurement of oral mucositis in children: a review of the literature

Evaluation of the memorial delirium assessment scale (MDAS) for the screening of delirium by means of simulated cases by palliative care health professionals

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie